---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-079036"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-03-18T23:59:59+00:00"
generated_at: "2026-06-26T21:38:56.170322+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences appoints Barbara K. Finck, M.D. to Board of Directors

## Summary
- Appointment effective March 16, 2022; Dr. Finck will serve as a Class I director until 2024 annual meeting.
- Annual cash retainer of $40,000, paid quarterly in arrears on a pro-rata basis.
- Granted option for 50,000 shares of common stock vesting monthly over three years.
- Dr. Finck currently acting Chief Medical Officer at Coherus BioSciences; prior CMO at NKT Therapeutics and Osprey Pharmaceuticals.
- No arrangement with any other person for election; no family relationships with directors or officers.

## SEC filing metadata
- accession: 0001193125-22-079036
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/0001193125-22-079036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/d322296d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-079036
- JSON: https://secwatch.observer/filing/0001193125-22-079036.json
- Plain text: https://secwatch.observer/filing/0001193125-22-079036.txt

## Key facts
- Executive change
  Barbara K. Finck, M.D. was appointed as Director at Forte Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Barbara K. Finck, M.D. to the Board, effective March 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/0001193125-22-079036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.